Navigation Links
BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010
Date:5/6/2010

SAN DIEGO, INDIANAPOLIS and WALTHAM, Mass., May 6, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.

"If approved, BYDUREON will be the first once-weekly treatment for type 2 diabetes, and we are committed to making this important therapeutic option available to patients as soon as possible," said Orville G. Kolterman, M.D., senior vice president of research and development, Amylin Pharmaceuticals. "We will continue to work closely with the agency through this final stage of the review process."

The new drug application (NDA) for BYDUREON was submitted in May 2009 and was based on data from the DURATION clinical trial program, as well as more than seven years of clinical experience with BYETTA® (exenatide) injection. The agency issued a complete response letter to the companies in March 2010 and the companies responded to that letter in April 2010.

BYDUREON (pronounced by-DUR-
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
2. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
5. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
6. AEterna Zentaris Announces Outcome of Managements Strategic Review
7. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
10. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 2014 XenoTech announces an exclusive ... metabolite production from bioactive small molecules. Based ... technology enables convenient and timely assessment of critical ... Vice President of Commercial Operations, Christian Darabant, “the ... risk can be measured directly by comparison with ...
(Date:8/19/2014)... Md. , Aug. 19, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today that its novel ... at the 54 th Interscience Conference on ... Washington D.C. ...
(Date:8/18/2014)... new therapy developed by researchers at the University ... and Columbia University Medical Center (CUMC) may help ... treatment. , The researchers demonstrated in a ... selectively inhibit blood vessel re-narrowing and simultaneously promote ... balloon catheter to open narrowed or blocked arteries. ...
(Date:8/18/2014)... devices with unprecedented efficiency and data storage ... use built-in electric polarizations to read and ... most popular data-driven technology. But ferroelectrics must ... including a curious habit of "forgetting" stored ... U.S. Department of Energy,s Brookhaven National Laboratory ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4
... and their Owners, ROCKVILLE, Md., June 23 ... a retriever retrieve? Why do Yorkshire terriers live,longer than ... be related,to a Great Dane?, (Photo: http://www.newscom.com/cgi-bin/prnh/20080623/AQM507 ... length and behavior more than any,other animal, and until ...
... NEW YORK, June 23 Medicsight PLC, a,subsidiary of ... an industry,leader in the development of Computer-Aided Detection (CAD) ... and Lucan Toh,(Director of Business Development) will be presenting ... 24th June., The conference will be held from ...
... Event June 27-28, 2008, NOVATO, Calif., June ... (OTC Bulletin Board:,RPTP), today announced that Ted Daley, ... Cystinosis Foundation Ireland,s 5th,International Cystinosis Conference to be ... City, Charlemont Place, Dublin 2, in Dublin, Ireland., ...
Cached Biology Technology:DNA Study Unlocks Mystery to Diverse Traits in Dogs 2DNA Study Unlocks Mystery to Diverse Traits in Dogs 3Medicsight to Present at Piper Jaffray Annual Europe Conference 2Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 2Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 3Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 4Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 5
(Date:8/20/2014)... few years, Virginia Tech,s Wu Feng has built upon ... the "Computing in the Cloud" program, and synergistically complemented ... award from the Air Force on "big computing" for ... the National Institutes of Health on "big data" for ... "parallel computing" aspects from each grant, he was able ...
(Date:8/20/2014)... new gene therapy developed by researchers at the University ... protect mice from a life-threatening heart condition caused by ... avenue," said Yi Lai, Ph.D., the leading author of ... School of Medicine,s Department of Molecular Microbiology and Immunology. ... this could lead to a treatment for people with ...
(Date:8/20/2014)... (PS1) absorbs light and its energy is finally ... biomass. Photovoltaic devices, mostly build from silicon based ... One approach for the development of cheaper and ... the isolated membrane protein complexes of photosynthesis. Prof. ... PS1 from thermophilic cyanobacteria that live in a ...
Breaking Biology News(10 mins):The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Gene therapy protects mice from lethal heart condition, MU researchers find 2A semi-artificial leaf faster than 'natural' photosynthesis 2
... John Bell said QUT had worked with a Canberra-based company ... both windows and energy generators in houses or commercial buildings. ... significant difference to home and building owners energy costs and ... on onsold. Professor Bell said the glass was one ...
... dramatically reduce damage caused by strokes the UK National ... (10 April). Speaking at the conference in Edinburgh, ... explain how combining scaffold microparticles with neural stem cells ... temporary loss of blood supply to the brain which ...
... 9, 2008) A study published in the April ... suggests an association between high egg consumption and all-cause mortality, ... an explanation. The researchers, Djouss and Gaziano, analyzed data from ... a 20 year period. The fact is, healthy adults ...
Cached Biology News:Scientists ask whether microscaffolding can help stem cells rebuild brain after stroke damage 2Statement by the American Egg Board and Egg Nutrition Center on AJCN study on egg consumption 2
Porcine IFN-gamma ELISpot Development Module...
RECOMBINANT EQUINE TNF ALPHA Product Type: Recombinant Protein...
TEMPLIPHI HT SEQ AMPL KIT, 1 EA. Category: Sequencing Template Amplification....
... The Vybrant Apoptosis Assay Kit ... of changes that occur in the permeability ... solutions of both YO-PRO-1 and propidium iodide ... through the plasma membranes of apoptotic cells ...
Biology Products: